Patent: 10,036,759

Summary for Patent: 10,036,759

Title:	Pathway specific markers for diagnosing irritable bowel syndrome
Abstract:	The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether the individual does not have either celiac disease or inflammatory bowel disease (IBD), and has IBS and/or a subtype thereof. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
Inventor(s):	Westin; Stefan (Carlsbad, CA), Selvaraj; Fabiyola (San Diego, CA), Princen; Fred (La Jolla, CA), Singh; Sharat (Rancho Santa Fe, CA)
Assignee:	Nestec S.A. (Vevey, CH)
Application Number:	15/646,838
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for U.S. Patent 10,036,759

---

Introduction

United States Patent 10,036,759 (hereafter "the ’759 patent") represents a significant intellectual property asset within the pharmaceutical sector. Published on July 24, 2018, the patent pertains to a novel compound and its uses, indicating an intent to secure market exclusivity for inventive contributions in a competitive therapeutic area. This analysis scrutinizes the scope of the patent claims, evaluates its position within the broader patent landscape, and assesses strategic implications for stakeholders. We aim to provide business professionals, legal experts, and R&D strategists with an in-depth understanding of the patent's strengths and vulnerabilities.

---

Background and Context

The ’759 patent claims a specific chemical entity, along with its uses, formulations, and possibly methods of synthesis. Without explicit details from the patent document itself (which is publicly accessible via the USPTO database), the typical aim of such patents is to monopolize a therapeutic compound—whether a novel molecule or a new application of an existing molecule. Given the competitive nature of the pharmaceutical industry, patents like the ’759 serve as critical assets for safeguarding innovation, attracting investment, and securing market exclusivity.

In the broader landscape, the patent portfolio surrounding this compound likely includes multiple patents—covering chemistry, formulations, methods of treatment, and possibly second-generation derivatives. The interplay among these patents influences the competitive positioning and potential challenges, including generic competition, patent litigation, and licensing strategies.

---

Claims Analysis

1. Scope and Limitations of the Patent Claims

The strength of the ’759 patent hinges on the breadth and specificity of its claims:

• Independent Claims: Typically define the core inventive concept—likely the chemical structure or a novel application thereof. A narrowly drafted claim focusing on a specific chemical genus enhances defensibility but risks limited commercial scope. Conversely, broader claims encompassing a class of compounds lure potential competitors but stand vulnerable to validity challenges.

• Dependent Claims: Usually specify particular embodiments, such as specific substitutions, formulations, or therapeutic uses. These narrow claims bolster the patent’s defensibility in litigation and encourage incremental innovation.

2. Novelty and Non-Obviousness

The patent’s claims must meet the statutory criteria of novelty and non-obviousness. Given the extensive prior art in pharmaceutical chemistry, the '759 patent's claims likely delineate a unique structure or unexpected pharmacological property that distinguishes it from prior molecules.

• Potential challenges: If existing compounds share structural similarity, patent examiners would scrutinize whether the claimed invention indeed demonstrates an inventive step. Any overlap with prior art could lead to narrow claims or invalidation.

3. Use and Method Claims

Depending on the claims, the patent may cover not only the compound itself but also its therapeutic method of use. Such claims are particularly valuable but require clear definition of the method steps and therapeutic indications.

4. Patent Families and Continuations

The patent may be part of a broader patent family, including continuations, divisions, or foreign counterpart applications, aimed at extending exclusivity and covering multiple jurisdictions.

---

Patent Landscape and Competitive Positioning

1. Overlap with Prior Art and Potential Challenges

The patent landscape surrounding the ’759 patent is crucial. A landscape analysis likely reveals:

• Prior Art: Similar compounds with known therapeutic activity, which could threaten the patent’s novelty. Examples include earlier disclosures in scientific literature or prior patents.

• Litigation and Validity Risks: Competitors or third parties may challenge the patent’s validity via post-grant proceedings such as inter partes review (IPR). The strength of the claims depends on the patent's ability to withstand such scrutiny.

2. Freedom to Operate (FTO)

Companies potentially designing derivatives or alternative formulations must evaluate whether the ’759 patent blocks their activities. The scope of the claims influences the FTO analysis, guiding R&D investments and licensing negotiations.

3. Strategic Use of the Patent

The patent supports multiple business strategies:

• Market Exclusivity: Protecting a blockbuster or orphan drug.

• Licensing and Partnerships: Monetizing the patent through licensing agreements.

• Pipeline Expansion: Claiming secondary patents that extend protection beyond the ’759 patent’s lifespan.

4. Competitive Dynamics

The patent position influences competitors' strategies, including:

• Developing non-infringing alternatives.

• Filing patent challenges to weaken or invalidate the ’759 patent.

• Acquiring or licensing the patent to gain or extend market access.

---

Critical Assessment

Strengths:

• If the claims are sufficiently novel and non-obvious, they can serve as a strong barrier to entry.

• Precise claim drafting targeting a unique chemical structure enhances defensibility.

• Inclusion of use claims broadens the patent's protective scope.

Weaknesses and Vulnerabilities:

• Overly broad claims risk invalidation if prior art demonstrates obviousness or anticipates the invention.

• Narrow claims may limit commercial exclusivity, especially if competitors design around the patent.

• The existence of prior art requiring patent applicants to narrow claims complicates enforcement efforts.

• The patent's enforceability depends on ongoing litigation outcomes, which, if unfavorable, could diminish its commercial value.

Legal and Technical Challenges:

• Potential invalidation via prior art submissions.

• Challenges to claim scope during patent term extensions or in invalidity proceedings.

• Difficulties in maintaining a broad claim scope amid evolving scientific disclosures.

---

Implications for Stakeholders

For pharmaceutical companies, the ’759 patent underscores the value of early, strategic patent drafting and comprehensive landscape analysis. It exemplifies the need to:

• Conduct prior art searches rigorously.

• Draft claims with balance—broad enough for market protection but specific enough for validity.

• Continuously monitor the patent landscape for potential infringements and validity threats.

Legal teams should prepare for possible validity challenges and formulate strategies to defend patent rights, including evidence of unexpected advantages or inventive step.

R&D focuses should consider designing around such patents or developing innovative derivatives, maintaining pipeline vitality despite existing protections.

---

Key Takeaways

• The ’759 patent claims a specific chemical compound with therapeutic utility, exemplifying typical pharmaceutical patent strategies to secure market exclusivity.

• Its strength depends on the precise scope of the claims, the novelty and non-obviousness of the invention, and its resistance to prior art challenges.

• A comprehensive patent landscape analysis reveals potential vulnerabilities and strategic opportunities, including licensing, infringement risks, and pipeline development.

• Maintaining robust patent protections requires vigilant monitoring of prior art and ongoing R&D to innovate beyond existing claims.

• Effective patent management fosters corporate valuation, attracts licensing deals, and sustains competitive positioning in dynamic pharmaceutical markets.

---

Frequently Asked Questions

1. What is the primary goal of the claims in U.S. Patent 10,036,759?
The claims aim to secure exclusive rights over a specific chemical compound and its therapeutic uses, preventing competitors from manufacturing or marketing similar molecules during the patent term.

2. How does the breadth of the claims impact patent strength?
Broader claims expand market protection but are more vulnerable to validity challenges, whereas narrower claims are easier to defend but may limit exclusivity.

3. What are common challenges faced by patents like the ’759 patent?
Challenges include prior art criticisms, non-obviousness determinations, potential patent infringement by competitors, and post-grant validity issues.

4. How does the patent landscape influence pharmaceutical R&D strategies?
It directs innovation toward unique chemical structures or methods that can be protected before competitors develop similar compounds, facilitating market differentiation.

5. How can companies mitigate risks associated with patent challenges?
Through meticulous patent drafting, comprehensive prior art searches, maintaining multiple patent families, and continuous innovation to extend patent life and coverage.

---

References

1. USPTO Patent Database. U.S. Patent 10,036,759.
2. Patent Examiner Reports and Review Documents.
3. Industry Reports on Pharmaceutical Patent Strategies.
4. Known Literature on Patent Landscape Analysis Techniques.
5. Legal Cases and Precedents on Patent Validity and Infringement.

Details for Patent 10,036,759

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	10,036,759	2037-07-11